RTW Biotech Opportunities (LON:RTW) Trading Down 1.3% - What's Next?

Key Points

• Price and volume: The stock was down 1.3% to GBX 1.91 on Friday, with trading volume of ~235,533 shares — a 78% decline from its average daily volume.
• Valuation and financials: Market cap is £6.23 million with a negative P/E (-0.07), a quick ratio of 0.81, current ratio of 1.26, and debt-to-equity of 22.51; the 50-day and 200-day SMAs are GBX 2.07 and GBX 1.92 respectively.
• Business focus: RTW Biotech Opportunities is an investment fund that targets transformative biopharmaceutical and medical technology companies and is managed by RTW Investments.

RTW Biotech Opportunities (LON:RTW - ) was down 1.3% during trading on Friday . The stock traded as low as GBX 1.89 and last traded at GBX 1.91. Approximately 235,533 shares traded hands during trading, a decline of 78% from the average daily volume of 1,081,214 shares. The stock had previously closed at GBX 1.94.

RTW Biotech Opportunities Price Performance

The stock has a market cap of £6.23 million, a P/E ratio of -0.07 and a beta of 0.77. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 22.51. The business's 50-day simple moving average is GBX 2.07 and its two-hundred day simple moving average is GBX 1.92.

RTW Biotech Opportunities Company Profile

RTW Biotech Opportunities Ltd LSE: RTW is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Bio invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Bio is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.